Sterile Formulation Development - Global 麻豆原创 Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Publication ID:

PB510247572

Publication Date:

October 11, 2024

Pages:

145

Publisher:

MRRPB5

Countries:

Global [1]

USD 3,950.00

IT Services [2]

Computing & Electronics [3]

Description:

The global market for Sterile Formulation Development was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
North American market for Sterile Formulation Development was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Sterile Formulation Development was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Europe market for Sterile Formulation Development was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global key companies of Sterile Formulation Development include Dalton Pharma Services, PCI Pharma Services, Bioprocess Online, Farbe Firma, Anglo Bio-Pharma Limited, Thermo Fisher Scientific, Pfizer CentreOne, Piramal Pharma Solutions and Ardena, etc. In 2023, the global five largest players hold a share approximately % in terms of revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Sterile Formulation Development, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Sterile Formulation Development by region & country, by Type, and by Application.
The Sterile Formulation Development market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Sterile Formulation Development.
麻豆原创 Segmentation
By Company
Dalton Pharma Services
PCI Pharma Services
Bioprocess Online
Farbe Firma
Anglo Bio-Pharma Limited
Thermo Fisher Scientific
Pfizer CentreOne
Piramal Pharma Solutions
Ardena
Curida
Curia Global
Carbogen Amcis
Woodstock Sterile Solutions
Cambrex
Aenova Group
Lonza
Catalent
PPD
Althea
Baxter
Segment by Type:
Liquid Dosage Form
Lyophilized Dosage Form
Frozen Dosage Form
Others
Segment by Application
Preclinical
Clinical
Commercial
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Sterile Formulation Development manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Sterile Formulation Development in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Sterile Formulation Development in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 麻豆原创 Overview
1.1 Sterile Formulation Development Product Introduction
1.2 Global Sterile Formulation Development 麻豆原创 Size Forecast
1.3 Sterile Formulation Development 麻豆原创 Trends & Drivers
1.3.1 Sterile Formulation Development Industry Trends
1.3.2 Sterile Formulation Development 麻豆原创 Drivers & Opportunity
1.3.3 Sterile Formulation Development 麻豆原创 Challenges
1.3.4 Sterile Formulation Development 麻豆原创 Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Sterile Formulation Development Players Revenue Ranking (2023)
2.2 Global Sterile Formulation Development Revenue by Company (2019-2024)
2.3 Key Companies Sterile Formulation Development Manufacturing Base Distribution and Headquarters
2.4 Key Companies Sterile Formulation Development Product Offered
2.5 Key Companies Time to Begin Mass Production of Sterile Formulation Development
2.6 Sterile Formulation Development 麻豆原创 Competitive Analysis
2.6.1 Sterile Formulation Development 麻豆原创 Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by Sterile Formulation Development Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Sterile Formulation Development as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Liquid Dosage Form
3.1.2 Lyophilized Dosage Form
3.1.3 Frozen Dosage Form
3.1.4 Others
3.2 Global Sterile Formulation Development Sales Value by Type
3.2.1 Global Sterile Formulation Development Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Sterile Formulation Development Sales Value, by Type (2019-2030)
3.2.3 Global Sterile Formulation Development Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Preclinical
4.1.2 Clinical
4.1.3 Commercial
4.2 Global Sterile Formulation Development Sales Value by Application
4.2.1 Global Sterile Formulation Development Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Sterile Formulation Development Sales Value, by Application (2019-2030)
4.2.3 Global Sterile Formulation Development Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global Sterile Formulation Development Sales Value by Region
5.1.1 Global Sterile Formulation Development Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Sterile Formulation Development Sales Value by Region (2019-2024)
5.1.3 Global Sterile Formulation Development Sales Value by Region (2025-2030)
5.1.4 Global Sterile Formulation Development Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America Sterile Formulation Development Sales Value, 2019-2030
5.2.2 North America Sterile Formulation Development Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe Sterile Formulation Development Sales Value, 2019-2030
5.3.2 Europe Sterile Formulation Development Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific Sterile Formulation Development Sales Value, 2019-2030
5.4.2 Asia Pacific Sterile Formulation Development Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America Sterile Formulation Development Sales Value, 2019-2030
5.5.2 South America Sterile Formulation Development Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa Sterile Formulation Development Sales Value, 2019-2030
5.6.2 Middle East & Africa Sterile Formulation Development Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Sterile Formulation Development Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Sterile Formulation Development Sales Value
6.3 United States
6.3.1 United States Sterile Formulation Development Sales Value, 2019-2030
6.3.2 United States Sterile Formulation Development Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Sterile Formulation Development Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Sterile Formulation Development Sales Value, 2019-2030
6.4.2 Europe Sterile Formulation Development Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Sterile Formulation Development Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Sterile Formulation Development Sales Value, 2019-2030
6.5.2 China Sterile Formulation Development Sales Value by Type (%), 2023 VS 2030
6.5.3 China Sterile Formulation Development Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Sterile Formulation Development Sales Value, 2019-2030
6.6.2 Japan Sterile Formulation Development Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Sterile Formulation Development Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Sterile Formulation Development Sales Value, 2019-2030
6.7.2 South Korea Sterile Formulation Development Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Sterile Formulation Development Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Sterile Formulation Development Sales Value, 2019-2030
6.8.2 Southeast Asia Sterile Formulation Development Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Sterile Formulation Development Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Sterile Formulation Development Sales Value, 2019-2030
6.9.2 India Sterile Formulation Development Sales Value by Type (%), 2023 VS 2030
6.9.3 India Sterile Formulation Development Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Dalton Pharma Services
7.1.1 Dalton Pharma Services Profile
7.1.2 Dalton Pharma Services Main Business
7.1.3 Dalton Pharma Services Sterile Formulation Development Products, Services and Solutions
7.1.4 Dalton Pharma Services Sterile Formulation Development Revenue (US$ Million) & (2019-2024)
7.1.5 Dalton Pharma Services Recent Developments
7.2 PCI Pharma Services
7.2.1 PCI Pharma Services Profile
7.2.2 PCI Pharma Services Main Business
7.2.3 PCI Pharma Services Sterile Formulation Development Products, Services and Solutions
7.2.4 PCI Pharma Services Sterile Formulation Development Revenue (US$ Million) & (2019-2024)
7.2.5 PCI Pharma Services Recent Developments
7.3 Bioprocess Online
7.3.1 Bioprocess Online Profile
7.3.2 Bioprocess Online Main Business
7.3.3 Bioprocess Online Sterile Formulation Development Products, Services and Solutions
7.3.4 Bioprocess Online Sterile Formulation Development Revenue (US$ Million) & (2019-2024)
7.3.5 Farbe Firma Recent Developments
7.4 Farbe Firma
7.4.1 Farbe Firma Profile
7.4.2 Farbe Firma Main Business
7.4.3 Farbe Firma Sterile Formulation Development Products, Services and Solutions
7.4.4 Farbe Firma Sterile Formulation Development Revenue (US$ Million) & (2019-2024)
7.4.5 Farbe Firma Recent Developments
7.5 Anglo Bio-Pharma Limited
7.5.1 Anglo Bio-Pharma Limited Profile
7.5.2 Anglo Bio-Pharma Limited Main Business
7.5.3 Anglo Bio-Pharma Limited Sterile Formulation Development Products, Services and Solutions
7.5.4 Anglo Bio-Pharma Limited Sterile Formulation Development Revenue (US$ Million) & (2019-2024)
7.5.5 Anglo Bio-Pharma Limited Recent Developments
7.6 Thermo Fisher Scientific
7.6.1 Thermo Fisher Scientific Profile
7.6.2 Thermo Fisher Scientific Main Business
7.6.3 Thermo Fisher Scientific Sterile Formulation Development Products, Services and Solutions
7.6.4 Thermo Fisher Scientific Sterile Formulation Development Revenue (US$ Million) & (2019-2024)
7.6.5 Thermo Fisher Scientific Recent Developments
7.7 Pfizer CentreOne
7.7.1 Pfizer CentreOne Profile
7.7.2 Pfizer CentreOne Main Business
7.7.3 Pfizer CentreOne Sterile Formulation Development Products, Services and Solutions
7.7.4 Pfizer CentreOne Sterile Formulation Development Revenue (US$ Million) & (2019-2024)
7.7.5 Pfizer CentreOne Recent Developments
7.8 Piramal Pharma Solutions
7.8.1 Piramal Pharma Solutions Profile
7.8.2 Piramal Pharma Solutions Main Business
7.8.3 Piramal Pharma Solutions Sterile Formulation Development Products, Services and Solutions
7.8.4 Piramal Pharma Solutions Sterile Formulation Development Revenue (US$ Million) & (2019-2024)
7.8.5 Piramal Pharma Solutions Recent Developments
7.9 Ardena
7.9.1 Ardena Profile
7.9.2 Ardena Main Business
7.9.3 Ardena Sterile Formulation Development Products, Services and Solutions
7.9.4 Ardena Sterile Formulation Development Revenue (US$ Million) & (2019-2024)
7.9.5 Ardena Recent Developments
7.10 Curida
7.10.1 Curida Profile
7.10.2 Curida Main Business
7.10.3 Curida Sterile Formulation Development Products, Services and Solutions
7.10.4 Curida Sterile Formulation Development Revenue (US$ Million) & (2019-2024)
7.10.5 Curida Recent Developments
7.11 Curia Global
7.11.1 Curia Global Profile
7.11.2 Curia Global Main Business
7.11.3 Curia Global Sterile Formulation Development Products, Services and Solutions
7.11.4 Curia Global Sterile Formulation Development Revenue (US$ Million) & (2019-2024)
7.11.5 Curia Global Recent Developments
7.12 Carbogen Amcis
7.12.1 Carbogen Amcis Profile
7.12.2 Carbogen Amcis Main Business
7.12.3 Carbogen Amcis Sterile Formulation Development Products, Services and Solutions
7.12.4 Carbogen Amcis Sterile Formulation Development Revenue (US$ Million) & (2019-2024)
7.12.5 Carbogen Amcis Recent Developments
7.13 Woodstock Sterile Solutions
7.13.1 Woodstock Sterile Solutions Profile
7.13.2 Woodstock Sterile Solutions Main Business
7.13.3 Woodstock Sterile Solutions Sterile Formulation Development Products, Services and Solutions
7.13.4 Woodstock Sterile Solutions Sterile Formulation Development Revenue (US$ Million) & (2019-2024)
7.13.5 Woodstock Sterile Solutions Recent Developments
7.14 Cambrex
7.14.1 Cambrex Profile
7.14.2 Cambrex Main Business
7.14.3 Cambrex Sterile Formulation Development Products, Services and Solutions
7.14.4 Cambrex Sterile Formulation Development Revenue (US$ Million) & (2019-2024)
7.14.5 Cambrex Recent Developments
7.15 Aenova Group
7.15.1 Aenova Group Profile
7.15.2 Aenova Group Main Business
7.15.3 Aenova Group Sterile Formulation Development Products, Services and Solutions
7.15.4 Aenova Group Sterile Formulation Development Revenue (US$ Million) & (2019-2024)
7.15.5 Aenova Group Recent Developments
7.16 Lonza
7.16.1 Lonza Profile
7.16.2 Lonza Main Business
7.16.3 Lonza Sterile Formulation Development Products, Services and Solutions
7.16.4 Lonza Sterile Formulation Development Revenue (US$ Million) & (2019-2024)
7.16.5 Lonza Recent Developments
7.17 Catalent
7.17.1 Catalent Profile
7.17.2 Catalent Main Business
7.17.3 Catalent Sterile Formulation Development Products, Services and Solutions
7.17.4 Catalent Sterile Formulation Development Revenue (US$ Million) & (2019-2024)
7.17.5 Catalent Recent Developments
7.18 PPD
7.18.1 PPD Profile
7.18.2 PPD Main Business
7.18.3 PPD Sterile Formulation Development Products, Services and Solutions
7.18.4 PPD Sterile Formulation Development Revenue (US$ Million) & (2019-2024)
7.18.5 PPD Recent Developments
7.19 Althea
7.19.1 Althea Profile
7.19.2 Althea Main Business
7.19.3 Althea Sterile Formulation Development Products, Services and Solutions
7.19.4 Althea Sterile Formulation Development Revenue (US$ Million) & (2019-2024)
7.19.5 Althea Recent Developments
7.20 Baxter
7.20.1 Baxter Profile
7.20.2 Baxter Main Business
7.20.3 Baxter Sterile Formulation Development Products, Services and Solutions
7.20.4 Baxter Sterile Formulation Development Revenue (US$ Million) & (2019-2024)
7.20.5 Baxter Recent Developments
8 Industry Chain Analysis
8.1 Sterile Formulation Development Industrial Chain
8.2 Sterile Formulation Development Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Sterile Formulation Development Sales Model
8.5.2 Sales Channel
8.5.3 Sterile Formulation Development Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer

Companies Mentioned:

Dalton Pharma Services
PCI Pharma Services
Bioprocess Online
Farbe Firma
Anglo Bio-Pharma Limited
Thermo Fisher Scientific
Pfizer CentreOne
Piramal Pharma Solutions
Ardena
Curida
Curia Global
Carbogen Amcis
Woodstock Sterile Solutions
Cambrex
Aenova Group
Lonza
Catalent
PPD
Althea
Baxter

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.